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Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease
that predominantly affects women in their fifth and sixth decades. The
diagnostic hallmarks of PBC are detection of anti-mitochondrial antibodies (AMAs) and chronic non-suppurative destructive cholangitis (CNSDC)
of small- and medium-sized intrahepatic bile ducts in liver histological
examination [1, 2]. A significant amount of data suggests that immunological activity against small biliary epithelial cells (BECs), found histologically as portal inflammation, leads to clinical disease. In PBC, as with
other autoimmune diseases, both genetic and environmental factors
contribute to the development of pathology [3–8]. The first-line therapy
of PBC is ursodeoxycholic acid (UDCA), although obeticholic acid (OCA)
has been approved recently for patients with an incomplete response
to UDCA [9–11]. Unfortunately, unlike other autoimmune diseases, no
successful clinical trials of biologics have been conducted, and the mechanisms of action of UDCA and OCA are not fully understood [12–16].
The clinical phenotype and the natural history of PBC vary between patients and can have other overlapping autoimmune diseases [12, 17–19].
For example, some patients may have mild elevation of liver enzyme levels
and remain asymptomatic for life. By contrast, other patients can develop
signs of liver failure and rapidly decompensate despite therapy, requiring
liver transplantation. A presumption is that these differences are due to
genetic and environmental factors, both contributing to the development
of PBC to various degrees in each patient [4, 7, 20]. Although multiple genome-wide association studies (GWASs) have been reported differences
in several genes [21–24], their clinical implications and relevance remain
elusive [25]. In fact, in PBC, in autoimmune diseases, including PBC, the
results of GWASs have been disappointing, and efforts have been made
recently for both deep sequencing and study of epigenetic events [26–30].
To understand the importance of developing a useful mouse model, other
aspects of PBC such as spectra of disease and gender dominance should
be considered [18, 31].

Toward solving the etiological mystery
Most autoimmune diseases, including PBC, have a strong sex bias towards women [32, 33]. Male and female immune responses differ and
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Efforts to establish mouse models of PBC

are affected by sex hormones, X-linked genes, and
sex-specific microbiota [34–38]. Despite extensive
studies with clinical samples and animal models
of PBC, no demonstrated physiological mechanisms account for the strong female predominance in PBC [32, 39–48]. Epidemiological studies
on PBC show that frequent exposure to environmental chemicals such as nail polish, chemicals in
tobacco smoke, and hormone replacement therapies are significantly associated with an increased
risk of PBC [7]. Other PBC risk factors include
recurrent urinary tract infections and increased
prevalence of reproductive complications [49, 50].
These risk factors may work synergistically in accelerating loss of tolerance. One theory proposes
that haploinsufficiency for specific X-linked genes
leads to female susceptibility to PBC and suggests
that enhanced monosomy X in the peripheral lymphocytes of affected women plays a role in the
induction of PBC [51, 52]. However, how these
genetic and environmental factors interact with
the immune system to elicit autoimmunity in PBC
remains unclear [53].
Newly diagnosed PBC patients are often past
their initial stages and present with elevated
cholestatic enzymes, AMA positivity, and dense
aggregation of lymphocytes in the liver. Investigation of these patients for very early events of
PBC is therefore inappropriate, and animal models that reflect many of the important aspects of
the disease are much needed. The animal model
should have the same physiological mechanisms
that are observed in human PBC, such as female
predominance; chronic cholestasis; AMA production; histological features, including lymphocyte
infiltration into the liver; and bile duct immune
involvement.

Several groups including, our own, have established mouse models of PBC in a spontaneous or
induced manner (Table I). These mice share some
of the important clinical phenotypes of PBC, including portal lymphocytic infiltration, presence of
AMA against mitochondrial antigens, and chronic
cholestasis.

Spontaneous murine models
The NOD.c3c4 mice, which have multiple B6and B10-derived insulin-dependent diabetes (Idd)resistant alleles on chromosomes 3 and 4, respectively, of the non-obese diabetic (NOD) mice. NOD.
c3c4 mice were demonstrated to be protected
from autoimmune diabetes and spontaneously develop lymphocytic peribiliary infiltrates and AMA
positivity [54, 55]. AMAs were detectable in 60%
(3/5) and 57% (4/7) of mice at 9–10 weeks and
14–20 weeks of age, respectively, and were directed against the inner lipoyl domain of PDC-E2, the
same mitochondrial autoantigens as recognized
in human PBC [54]. Moreover, it is noteworthy that
AMA detection was observed in female mice, indicating female predominance like in human PBC.
However, pathological examination of the liver
revealed biliary polycystic diseases in both intrabiliary and extrabiliary ducts, and little evidence of
CNSDC. The expression levels of anti-PDC-E2 antibodies declined as the mice got older. Chronic biochemical cholestasis was not observed. Nevertheless, NOD.c3c4 mice clearly indicated that genetic
manipulation in a susceptible strain could produce
AMA with identical antigenicity as human PBC for
the first time, supporting the importance of genetic contribution to PBC.

Table I. Characteristics of some PBC mouse models
Clinical and
immunological
features

Spontaneous model
Ae2a,b

mice

ARE Del

dnTGFbRII

Female
dominance

Yes

No

No

No

Yes

No

Cholestasis

–

+

–

Yes

+

+

AMA
seropositivity

50–60%

100%

100%

30%

100%

100%

Portal
inflammation

+++

+++

+++

++

++

+

+

–

–

_

+

+

Biliary
polycystic
lesions

Moderate
colitis

Severe
anemia,
inflammatory
bowel
diseases, and
short life span

Osteopetrosis
in long bones

Mild lupuslike disease

Peritonitis

Granulomas
Other features

IL-2Ra

Induced
model
2-OA-BSA
immunized

NOD.c3c4

–/–

–/–

–/–
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The dominant-negative TGF-b receptor II
(dnTGFβRII) mice, studied intensively by our
group, also mimicks phenotypes of human PBC
[56]. These mice are transgenic for the directed expression of a dominantly negative form
of TGF-β receptor type II, under the direction of
the CD4 promoter. Thus, TGF-b signaling is not
completely abolished and dnTGFβRII mice can
survive as do non-transgenic mice. DnTGFβRII
mice spontaneously produce AMAs directed to
the same mitochondrial autoantigens as in human PBC, namely PDC-E2, BCOADC-E2, and OGDC-E2. By weeks 22–24, 100%, 95%, and 68% of
the mice sera reacted with PDC-E2, OGDC, and
BCOADC, respectively. Lymphocytic liver infiltration with periportal inflammation is analogous
to the histological profile of human PBC (Figure 1). In addition, the serum cytokine profile of
affected mice mimics data in human PBC. DnTGFβRII mice, although lacking female predominance, demonstrate the role of TGF-b pathways
in the immunopathogenesis of PBC and served
as a model for investigating the efficacy of B-cell
depletion therapy for PBC [57].
The third spontaneous mouse model is IL-2Rα–/–
mice, lacking IL-2R that is crucial for differentiation
of regulatory T cells (Tregs) and eventually reduction in Tregs [58]. We reported the case of a 5-yearold boy with IL-2a deficiency who developed liver
dysfunction with serological expression of PBC,
and documented paucity in the frequency and
absolute numbers of circulating CD4+CD25high natural Tregs in patients with PBC and their first-degree relatives [59]. These observations prompted
us to examine whether IL-2Ra–/– mice would serve
as PBC model mice. The results were striking because the mice developed portal inflammation,
biliary ductular damage, and a Th1 cytokine bias
in sera, resembling human PBC. In addition, AMAs
were detectable in all IL-2Ra–/– mice and targeted to the inner lipoyl domain of PDC-E2. However, female predominance was not observed in the
IL-2Ra–/– mice. Furthermore, absence of granulomas, short life span, and presence of clinical manifestations such as anemia and inflammatory bow-

A

B

el diseases made the IL-2Ra–/– mice less attractive
as a PBC model mice.
The fourth spontaneous model is the Ae2a,b–/–
mice. AE2 is an Cl–/HCO3– anion exchanger 2 which
is involved in intracellular pH regulation and
trans-epithelial acid-base transport. In 2008, Salas
et al. reported that Ae2a,b–/– mice develop elevated levels of IL-12p70 and IFN-γ and increased
numbers of CD8+ T cells. Interestingly, AMA and
increased levels of IgM, IgG and alkaline phosphatase were also observed in Ae2a, b–/– mice. Histologically, 30% of Ae2a,b–/– mice showed infiltration
of CD4+ and CD8+ T cells in the portal areas and
around the damaged bile duct with slight fibrosis
around areas of bile duct obstruction [60].
The mechanism of this model has been explained by a change in biliary epithelial cell homeostasis due to AE2 deficiency, which increases
intracellular pH and promotes the proliferation,
differentiation and activity of lymphocytes, leading to an increase in the targeting sensitivity of
CD8+ T cells, leading to biliary pathology. Although
Ae2a,b–/– mice develop hepatobiliary and immunological features resembling human PBC, the
large variations in liver pathology, lack of female
predominance and difficulties in breeding made
Ae2a,b–/– mice limit its applications for preclinical
studies.

Induced murine models
The three above-mentioned mice spontaneously developed serological and immunopathological features that mimic human PBC
after genetic manipulation (Table I), clearly indicating the importance of genetics in the development of the disease. Meanwhile, robust evidence
supports the crucial contribution of environmental factors; in this regard, stimulation of genetically susceptible mice with environmental factors
would be another attractive approach for breaking immunological tolerance against PDC-E2. To
establish these “induced” mice model, we have
studied chemical xenobiotics as potential environmental factors, particularly and hypothesized
that xenobiotic modification of native PDC-E2

C

Figure 1. Histological features of the liver in dnTGFβRII mice at 24–28 weeks. Different degrees of lymphocytic
infiltrations (red arrows) surrounding the small bile ducts, within the portal tracts (hematoxylin-eosin staining) [56]
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could elicit autoimmune response to PDC-E2 and
break tolerance.
Based on a detailed, quantitative structure-activity relationship analysis with 107 potential xenobiotic mimics coupled to the lysine residue of
the immunodominant 15-amino acid peptide of
the PDC-E2 inner lipoyl domain, we found that PBC
sera were more reactive to a number of xenobiotics
modified PDC-E2 peptide than to the native lipoylated peptide. Among them, 2-Octynoic acid (2-OA)
was unique in both its quantitative structure-activity relationship analysis and reactivity [20]. 2-OA is
a xenobiotic chemical that is widely used as a cosmetic ingredient and for seasoning foods. Thus, we
immunized C57BL/6 mice with 2-OA coupled to
bovine serum albumin (BSA; Figure 2) and demonstrated that anti-PDC-E2 antibodies were seropositive as early as 4 weeks after immunization (Figure 3), indicating tolerance breakdown against
PDC-E2 with xenobiotic immunization. In addition,
these mice have shown portal infiltration of CD4+
and CD8+ T cells and granulomas, and elevation of
TNF-a and IFN-g expression levels [61]. Therefore,
2-OA-BSA-immunized mice provides a suitable
model for investigating immunopathogenesis in
the early stage of PBC and for testing the therapeutic efficacy of new compounds.
To further investigate potential roles of cytokine pathways, we systemically constructed several unique gene-deleted mice, including mice
with IL-12p40, IL-12p35, IFN-g, IL-23p19, IL-17A,
IL-17F, and IL-22 deletions. Then, we immunized
these mice with 2-OA-BSA and followed their natural history [62]. The results are summarized as
follows: (1) both IL-12/T helper type 1 (Th1) and
IL-23/Th17 were involved in autoimmune cholangitis, (2) the IL-12/Th1 signaling pathway elicited pathology, and (3) IFN-γ deletion prevented
autoimmune cholangitis (Figure 4). Furthermore,
2-OA-BSA mice were also studied for the potential
efficacy of CTLA-4-based therapy on cholangitis by
using CTLA4-Ig [63].
In summary, these model mice develop clinical
and immunological characteristics as human PBC,
including cholestasis, AMA positivity, and portal
inflammation. However, female predominance, an
important feature of PBC and other autoimmune
diseases, was not manifested in most of the mice
except for NOD.c3c4 mice. A mouse model with
immunological characteristics of PBC and female
predominance will more closely reflect the human
disease. Therefore, we focused on IFN-g based
on extensive efforts of Dr. Howard Young et al.
on a interesting IFN-g designer mouse, described
below, and also in part on numerous studies that
reported that IFN-γ plays an essential role in the
development and severity of female-dominant autoimmune diseases [34].

IFN-g as a key molecule of PBC
There are several lines of evidence that IFN-γ
is involved in the pathogenesis of autoimmune
cholangitis: (i) Immunohistochemistry staining in
PBC livers demonstrates that, IL-12/Th1 cytokines
are dominant in the inflamed portal area with
IFN-γ-positive monocular cells surrounding degenerated cholangiocytes in the early stage of
disease, whereas the Th1/Th17 balance is skewed
toward IL-23/Th17 in advanced stages of PBC [64].
(ii) As described previously, liver histology in a xenobiotic induced model demonstrated that both
IL-12/Th1 and IL-23/Th17 are involved in cholangitis but indicated that the IL-12/Th1 signaling
pathway elicits pathology. The disease was prevented by IFN-γ deletion (Figure 4) [62, 65]. (iii)
Th17 signaling suppressed the accumulation of
IFN-γ-producing cells in the liver during the early
phase of cholangitis [62], supporting the hypothesis that IFN-γ is a key factor in the induction of biliary autoimmunity. Thus, we emphasize that the
pathology of PBC is mediated through IFN-γ-related pathways. For example, one may postulate that
OH
2-octynoic
acid
O

NHSCH3OCH3

N

O
NHS-activated
2-octynoic acid

O

O

O

BSADMSO
Z
BSA-conjugated
2-octynoic acid

NH

O

K
Lipoic acid

NH

O
S

S

Figure 2. Structures of lipoic acid and 2OA-BSA.
2OA is conjugated with BSSA and used for immunization. “Z” represents any lysine residue of BSA.
NHS, N-hydroxysuccinimide [61]
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A

B 0.8
1.6

IgA-AMA (OD)

IgG-AMA (OD)

0.6
1.2

0.8

0.4

0.2

0.4

0

0
0

4
8
Post immunization [weeks]
2OA-BSA
BSA

12

0

4
8
Post immunization [weeks]
2OA-BSA
BSA

12

C 0.4

IgM-AMA (OD)

0.3

0.2

0.1

0
0

4
8
Post immunization [weeks]
2OA-BSA
BSA

12

Figure 3. Detection and quantification of antiPDC-E2 antibody in sera of 2-OA-BSA-immunized
mice by using enzyme-linked immunosorbent assay at 2-week intervals after immunization. Significant increase in optical density (OD) were observed
after immunization between the responders and
controls [61]

B6IFN-g–/–

Figure 4. IFN-g knockout completely abolished autoimmune cholangitis. Portal inflammatory changes with interlobular bile duct damage (red arrow) were observed in wild-type mice (B6 mice) and normal bile ducts in IFN-g–/–
mice (blue arrows) [62]
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after a liver environmental insult, local up regulation of IFN-γ in a genetically susceptible host will
lead to loss of tolerance. These events may occur
serially, each leading to an up regulation of MHC
in target tissue, further contributing to an autoimmune response. We should note that activation
of naive CD4 T cells from healthy women produces higher levels of IFN-γ and lower levels of IL-17
than those from healthy men [66]. Increased IFN-γ
levels have also been demonstrated in patients
with autoimmune diseases [34, 67]. However,
no optimal model has been developed to determine how IFN-γ and gender together could elicit
female-biased cholangitis in patients with PBC.
In particular, whether IFN-γ is the first trigger in
breaking tolerance needs to be addressed.

An ARE Del–/– mice as a novel PBC model
To solve this problem, we took advantage of
a “designer” mouse with dysregulation of IFN-γ,
in which adenylate uridine-rich element (ARE) of
the IFN-γ 3'-untranslated region was deleted [68].
In these mice, regulation of IFN-γ is disrupted and
is constantly produced.
The ARE Del–/– mice have mild autoimmune
manifestations similar to lupus early in life. Adult
mice reflect many symptoms similar to human
PBC, including liver histology, AMA production,
and elevation of serum total bile acid (TBA) levels
[69]. Furthermore, these features are predominantly found in female mice. In male ARE Del–/–
mice, portal inflammation was scarcely found,
and serum titers of AMA were elevated but not
significantly in comparison with those in wildtype mice (Figure 5). The TBA levels were comparable. Furthermore, gene expression analysis
revealed that upregulated genes in female ARE
Del–/– mice specifically overlapped with the gene
expression signature of BECs in human PBC.
Therefore, female ARE Del–/– mice mimic human
PBC closely, making ARE Del–/– mice an ideal PBC
mouse model.

Female predominance occurs in ARE Del–/– mice
probably because female hormones and genetics shape the immune system in female mice to
generate more IFN-γ-producing cells. On the other
hand, male mice may be protected by androgens,
which favor up regulation of regulatory cells and
down regulation of IFN-γ-producing cells. Female
hormones activate the T lymphocytes to express
more IFN-γ in female mice in this mouse model.
Although many spontaneous and induced murine
models have been reported as PBC mouse models
[65], no single model has exhibited female dominance as observed in this ARE Del –/– mice.
IFN-γ may play a pathogenic role in BECs in the
initiation stage of PBC, and alteration of expression levels of IFN-γ would be critical for the development of PBC in susceptible individuals. Furthermore, we demonstrated that transfer of CD4
T cells from ARE Del–/– mice to B6/Rag1–/– mice
(an immune-deficient strain lacking mature T or
B cells) induced moderate portal and parenchymal
inflammations, implying that CD4+ T cells mainly
contribute to the induction of cholangitis [69].

What then are the therapeutic targets in PBC?
Although the pathogenesis of PBC is still not
fully understood, progression of the disease from
early to late stage is divided into 3 steps: (i) loss of
tolerance against PDC-E2, which leads to inflammation and bile duct damage; (ii) insults to BECs
with toxic bile acids due to chronic cholestasis;
and (iii) liver fibrosis. Thus, treatment targets are
mainly considered as inhibition of autoimmunity
or modification of lymphocytes targeted to the
liver, detoxification of harmful bile acids, and reversal of the fibrotic process [31]. As anti-fibrotic
drugs are expected to be effective for all liver diseases regardless of etiologies, we will focus on the
modification of autoimmunity and detoxification
of harmful bile acids (Table II).
PBC is an autoimmune-mediated liver disease,
and homing of autoantigen specific T lymphocytes

0.3

0.3

OD

B 0.4

OD

A 0.4

0.2

0.2

NS
NS
NS

0.1

0.1

0

0
PDC-E2
WT

OGDC-E2
ARE

BCOADC-E2

PDC-E2
WT

OGDC-E2
ARE

BCOADC-E2

Figure 5. AMA levels in ARE-Del–/– female (A) and male (B) mice at 20 weeks [69]
WT – wild type.
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to the liver plays a crucial role in its pathogenesis.
However, clinical trials with immunosuppressive
agents have essentially failed, including corticosteroids, methotrexate, azathioprine budenoside and
select biologics. Among these trials, B-cell depletion
with anti-CD20 had been expected to be effective
in PBC [57]. Although non-specific inhibition of activation of T cells was thought to be a candidate for
therapeutic trials, overall results from clinical trials
with anti-CD40, chimeric CTLA4 (abatacept), and anti-IL12/IL23 (ustekinumab) were disappointing [70].
Biliary epithelial cells damaged by innate and/
or acquired immunity impede smooth flow of
bile within the bile ducts, which leads to chronic
cholestasis. In normal conditions, the “bicarbonate umbrella”, a layer of secreted bicarbonate
onto biliary epithelial cells, protects them from
toxic bile acids. Impairment of this umbrella contributes to development of cholestasis in PBC [71].
Hydrophobic bile acids such as lithocholic acid
are highly toxic to biliary epithelial cells and hepatocytes. Therefore, reducing the toxicity of hydrophobic bile acids through decreasing bile acid
synthesis and stimulating choleresis would be
another possible regimen in cholestatic liver diseases such as PBC [72]. So far, many compounds
have been developed for detoxification of hydrophobic bile acids, and mechanisms of these drugs
are largely classified into three categories: reduction of intrahepatic de novo synthesis of bile acids, choleresis through modification of hepatic bile
acid transporters, and blocking bile acid transporters at the ileum for disturbing the reabsorption of
bile acids [73].

Modification of autoimmunity
Rituximab that leads to B-cell depletion and
ant-fractalkine antibody were expected to be effective and clinical trials are in preparation. Rituximab is anti-CD20 antibody, clinically used for
several indications associated with B lymphocytes
such as non-Hodgkin lymphoma. B-cell depletion
with anti-CD20 antibody ameliorates cholangitis
in dnTGF-bRII mice, but preliminary data in clin-

ical trials suggested conflicting results [74, 75].
Recently, several novel anti-CD20 antibodies have
been developed and approved for B-cell lymphoma [76] and are expected to be investigated in
patients with PBC as well.
Pathogenic T lymphocytes are activated and
recruited into the vicinity of the bile ducts from
the portal vein. During this homing process of
T lymphocytes, chemokines play an important
role. Previous studies demonstrated that CX3CL1
(a chemokine called fractalkine) production was
augmented with TLR3 by biliary epithelial cells in
PBC, and CX3CR1 (the receptor of fractalkine)-positive lymphocytes invade into biliary tract by engaging CX3CL1, thereby causing cholangitis [77].
Anti-fractalkine antibody (E6011), originally developed for rheumatoid arthritis [78] and Crohn’s disease, is thus expected to be effective for PBC, and
the phase 2 trial of E6011 for PBC with incomplete
response to UDCA will be soon launched in 2017.

Obeticholic acid
Alternative treatment options for PBC patients
refractory to UDCA have been long awaited. In
2016, the Food and Drug Administration (FDA) officially approved OCA, based on the results of the
phase 3 clinical trial of OCA (POISE trial) [10]. OCA is
a selective ligand of the farnesoid X receptor (FXR).
Bile acid toxicity against biliary epithelial cells and
hepatocytes is decreased by FXR signaling through
impairment of bile acid synthesis and stimulation
of choleresis. The endogenous FXR ligand is chenodeoxycholic acid (CDCA), a primary bile acid. Compared with CDCA, OCA is approximately 100 times
more potent than CDCA in activating FXR [79].
In the POISE trial, 217 patients with PBC who
showed an inadequate response (serum alkaline
phosphatase (ALP) level of > 1.67 × ULN) or an abnormal total bilirubin level (< 2 times × ULN), or
intolerance to UDCA were enrolled and received
5–10 mg of OCA, 10 mg of OCA, and placebo for
1 year. The primary end point was ALP level of
< 1.67 × ULN with > 15% reduction from the baseline and normal bilirubin level. Of the patients,

Table II. Pathogenic and therapeutic targets of PBC
Mechanisms

Drug name

Drug class

Phase of development

Modification of
autoimmunity

Abatacept
Ustekinumab
Rituximab
E6011

Chimeric CTLA4
Anti-IL12 Ab
Anti-CD20 Ab
Anti-fractalkine Ab

Phase 4
Phase 2
Phase 2
Phase 2

Detoxification
of toxic bile
acids

Obeticholic acid
Fenofibrate
Bezafibrate
GSK2330672

FXR agonist
Fibrates
Fibrates
Inhibitors of ileal bile acid
transporter
FGF19

Approved and phase 4
Phases 2 and 3
Phase 2
Phase 2
Phase 2
Phase 2

NGM282
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46–47% of patients achieved the primary end
point [10]. Consequently, OCA received accelerated FDA approval on May 27, 2016.
While OCA has become the second-line drug
officially approved for PBC and is well accepted,
it remains suboptimal for several reasons: First,
the response rate was at most 50%, which means
that half of the patients did not respond to OCA.
Second, pruritus, a frequent symptom of PBC,
appeared as an adverse effect in 56–68% of patients treated with OCA. Furthermore, whether
the primary end points (ALP level < 1.67 × ULN
with > 15% reduction from the baseline and normal bilirubin level) are associated with improvement of long-term outcomes has not been confirmed yet [80]. In this regard, follow-up studies
of the POISE trial were required by the FDA, and
a phase 3 study is currently ongoing (COBALT,
NCT02308111). Finally, OCA treatment should be
continued for patients refractory to UDCA; thus,
OCA may be prescribed lifelong along with UDCA.
Based on the high cost of OCA ($69,350 per year),
this unlimited prescription of OCA may cause substantial economic burden on both patients and
society, Samur et al. recently demonstrated that
the price should be decreased to $18,450 per year
to make OCA cost-effective [81].

Fibrates
Fibrates (fenofibrate and bezafibrate) were
originally labeled for dyslipidemia and used for
decreasing serum cholesterol and triglycerides.
Fibrates are PPAR-alfa and PXR agonists, resulting in reduction of de novo bile acid synthesis
and up regulation of bile acid transporters [82].
Bezafibrate was first reported as biologically effective for PBC patients refractory to UDCA in
1999 [83]; since then, it has been used as an
off-label second-line drug in Japan. A large-scale
retrospective cohort study in Japan demonstrated that patients with good response to bezafibrate (normalization of ALT) exhibited a comparable prognosis to those treated with UDCA
alone and significantly better outcomes than
those with poor response to bezafibrate [84]. Recently, a prospective randomized study in Japan
revealed that long-term outcomes were not significantly different between the UDCA plus bezafibrate and UDCA only groups, but the sample
size in this study might be too small to establish
enough statistical power [85]. Another prospective, randomized phase 3 study of bezafibrate
for patients with PBC with incomplete responses
to UDCA is ongoing in France (NCT01654731).
Fenofibrate was reported to decrease serum
ALP levels in studies in Japan and China [86, 87],
while adjunct use of fenofibrate to UDCA showed
no association with decreased serum ALP levels

in a UK cohort [88]. Participants are being recruited for a prospective randomized study in China
(NCT02965911). However, these two prospective
clinical trials showed improved liver enzyme levels notably at 12 or 24 months as the primary
end point. Even after these trials are terminated, whether long-term outcomes are improved
with additional treatment with fibrates is still
unknown, and follow-up studies of these trials
are needed.

Ileal bile acid transporter inhibitors
Bile acids are essential to the human body, and
98% of bile acids excreted into the intestine are
reabsorbed from the ileum bile acid transporter
(IBAT) and returned to the liver via portal tract,
known as enterohepatic circulation. In cholestatic
liver disease, ileal bile acid absorption is increased
[89]. Therefore, another strategy for reducing bile
acids is blocking IBAT. One of these compounds,
GSK2330672, did not significantly decrease serum
ALP levels in patients with incomplete responses
to UDCA but was demonstrated to significantly
improve pruritus in comparison with placebo [90].
A prospective, randomized, placebo-controlled
phase 2 study of GSK2330672 is launched in 2017
(NCT02966834).

Future direction with the ARE Del–/– mouse
model
Although PBC is clearly a heterogeneous disease, the therapeutic approach is similar for all
patients and not satisfactory at all even with OCA.
This is partly due to the lack of animal models that
could be used for investigating the immunopathology of PBC and the efficacy of newly developed
compounds. In this regard, ARE Del–/– mice, which
closely mimic human PBC, is currently the most
attractive model. ARE Del–/– mice provides the following benefits. First, this is a female-predominant
model for PBC, which allows for investigation on
mechanisms of female predominance in the disease. We can conduct a comprehensive analysis on
sexual dimorphic physiological systems, including
hormones, immune differences, and microbiome.
We can alter estrogen and estrogen receptors on
cells to study their effect on disease process and
pathology. We can also examine the female microbiome to resemble the male microbiome and raise
these mice in a germ-free environment for further
systematic introduction of selected bacteria. Second, this model will aid in determining which gene
pathways may help or hinder the progress of PBC
in both sexes. Third, this model also enables us
to examine over time the interaction of multiple
cellular messengers and their role in the development of autoimmune state. Finally, this model has
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vast implications for clinical research. It allows for
examination of the heterogeneity and the natural
history of PBC, from the early, asymptomatic stage
to the late stage and the possibility to discover
new biomarkers along different stages. This mouse
also provides an effective tool for assessing the effect of drugs currently used or under development,
and for designing novel, more-effective drugs for
the clinical management of PBC.
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